Estrella Immunopharma Inc. announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS® T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas (NHL). According to the company, the study achieved a 100% complete response rate at Month 1 in all evaluable patients in this cohort, which included individuals with relapsed or refractory B-cell NHL who had failed multiple prior therapies and were considered high-risk, including one patient with central nervous system involvement. No treatment-related serious adverse events were reported. The data from this phase will be reviewed by an independent Data and Safety Monitoring Board to determine the recommended Phase II dose for the expansion phase of the trial. These results have already been announced by the company.